Imunon (IMNN)
NASDAQ:IMNN
Want to see IMNN full AI Analyst Report?
IMNN Stock Chart & Stats
$3.10
-$0.06(-6.43%)
At close: 4:00 PM EST
$3.10
-$0.06(-6.43%)
Day’s Range― - ―
52-Week Range$2.52 - $41.22
Previous CloseN/A
Volume151.93K
Average Volume (3M)151.00K
Market Cap
$10.98M
Enterprise Value-$789.26K
Total Cash (Recent Filing)$8.78M
Total Debt (Recent Filing)$1.01M
Price to Earnings (P/E)―
Beta-0.76
Next Earnings
May 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.00
Shares Outstanding3,922,764
10 Day Avg. Volume37,799
30 Day Avg. Volume151,001
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.15
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market Cap-0.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.30
Enterprise Value/Ebitda0.06
Forecast
1Y Price Target
$15.67Price Target Upside405.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.82
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Efficacy ResultsPhase 2 OVATION 2 reported a substantial overall survival benefit for newly diagnosed advanced ovarian cancer patients treated with IMNN-001 added to standard therapy, indicating strong clinical activity.
Phase 3 Trial Design And EnrollmentPhase 3 OVATION 3 enrollment is progressing ahead of expectations and the trial's high statistical power with adaptive interim analyses could enable an earlier regulatory filing if early efficacy is observed.
Synergy With Existing TherapiesA subgroup receiving PARP inhibitor maintenance alongside IMNN-001 showed an especially large survival benefit, suggesting meaningful synergy with established maintenance treatments.
Bears Say
Cash Runway And Funding RiskLimited cash on hand creates funding risk and indicates additional capital will likely be needed to complete late-stage development.
Expense Control And Operational ConstraintsCareful control of spending is necessary to support continued patient enrollment and activation of trial sites, signaling operational constraints that could hinder trial progress if costs rise.
Financing And Dilution RiskPlans for equity raises, use of an at-the-market program, and potential warrant exercises increase the likelihood of shareholder dilution while securing funds for clinical milestones.
Imunon News
IMNN FAQ
What was Imunon’s price range in the past 12 months?
Imunon lowest stock price was $2.52 and its highest was $41.22 in the past 12 months.
What is Imunon’s market cap?
Imunon’s market cap is $10.98M.
When is Imunon’s upcoming earnings report date?
Imunon’s upcoming earnings report date is May 12, 2026 which is in 6 days.
How were Imunon’s earnings last quarter?
Imunon released its earnings results on Mar 31, 2026. The company reported -$1.241 earnings per share for the quarter, missing the consensus estimate of -$1.215 by -$0.026.
Is Imunon overvalued?
According to Wall Street analysts Imunon’s price is currently Undervalued.
Does Imunon pay dividends?
Imunon does not currently pay dividends.
What is Imunon’s EPS estimate?
Imunon’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Imunon have?
Imunon has 3,922,764 shares outstanding.
What happened to Imunon’s price movement after its last earnings report?
Imunon reported an EPS of -$1.241 in its last earnings report, missing expectations of -$1.215. Following the earnings report the stock price went up 2.083%.
Which hedge fund is a major shareholder of Imunon?
Currently, no hedge funds are holding shares in IMNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Imunon
Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.
IMNN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed strong, potentially transformative clinical momentum driven by a robust Phase II overall survival signal (14.7 months) and faster-than-expected Phase III enrollment, supported by translational data, publications, CRO support and cost discipline. However, near-term financing risk is acute (cash of $8.8M with runway into H2 2026), the registrational timeline extends to 2029 absent an early interim readout, and some scientific endpoints (MRD) remain exploratory. Management is actively pursuing financing and partnerships and has taken cost-saving measures to extend the runway, but successful execution of funding and completion of the Phase III program are critical next steps.View all IMNN earnings summariesIMNN Stock 12 Month Forecast
Average Price Target
$15.67
▲(405.38% Upside)
Technical Analysis
Ownership Overview
9.57% Insiders
1.17% Mutual Funds
<0.01% Other Institutional Investors
88.03% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---